Eylward Susan
Known title: General Counsel and Corp SecCIK: 0002039135
Associated companies
Transaction History
| IMNN | ▼ Sell | Open Market | 2,525 | $4K | 8/31/2026 | View on chart |
| IMNN | ▲ Buy | Grant | 2,525 | $4K | 8/28/2026 | View on chart |
| IMNN | ▼ Sell | Open Market | 2,449 | $4K | 8/17/2026 | View on chart |
| IMNN | ▲ Buy | Grant | 2,449 | $4K | 8/14/2026 | View on chart |
| IMNN | ▼ Sell | Open Market | 2,541 | $4K | 8/3/2026 | View on chart |
| IMNN | ▲ Buy | Grant | 2,541 | $4K | 7/31/2026 | View on chart |
| IMNN | ▼ Sell | Open Market | 2,150 | $4K | 7/20/2026 | View on chart |
| IMNN | ▲ Buy | Grant | 2,150 | $4K | 7/17/2026 | View on chart |
| IMNN | ▼ Sell | Open Market | 920 | $2K | 7/6/2026 | View on chart |
| IMNN | ▲ Buy | Grant | 920 | $2K | 7/2/2026 | View on chart |
| IMNN | ▼ Sell | Open Market | 11,800 | $21K | 6/29/2026 | View on chart |
| IMNN | ▲ Buy | Grant | 14,696 | $25K | 6/25/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Imunon Shares Debt Conversion and Ovarian Cancer Data
Imunon Inc. disclosed that it converted $1.2 million of debt into equity. Additionally, the company shared research data for IMNN-001 in frontline ovarian cancer during an R&D day. These updates provide context for the stock's current trading range, which remains well below the average analyst target price.
Imunon Shares Debt Conversion and Ovarian Cancer Data. Imunon Inc. disclosed that it converted $1.2 million of debt into equity. Additionally, the company shared research data for IMNN-001 in frontline ovarian cancer during an R&D day. These updates provide context for the stock's current trading range, which remains well below the average analyst target price.